The latest from NuvOx

Tucson, Arizona — April 30, 2026 — NuvOx Therapeutics (“NuvOx”), a clinical-stage biotechnology company developing oxygen therapeutics for life-threatening hypoxemic conditions, today announced positive preliminary results from the second cohort of its ongoing EXTEND Phase Ib clinical trial of NanO₂™ (dodecafluoropentane emulsion) in patients with mild respiratory distress. The results demonstrated stronger oxygenation signals with dose escalation while maintaining an excelle

Tucson, AZ – April 22, 2026 – Today NuvOx Therapeutics, Inc. (“NuvOx” or the “Company”), a clinical stage biopharmaceutical company developing a novel platform of oxygen therapeutics, today announced that it has entered into a research collaboration agreement with Department of Veteran Affairs (“VA”). The research project is to investigate whether NuvOx’s oxygen therapeutic product candidate, NanO₂™ (dodecafluoropentane emulsion), can improve oxygen delivery, as well as its

Tucson, AZ – March 10, 2026 – Today NuvOx Therapeutics, Inc. (“NuvOx” or the “Company”) announced that the first patient has been treated under a U.S. Food and Drug Administration (FDA)-authorized single-patient Expanded Access protocol for newly diagnosed glioblastoma at the Center for Neurosciences. The treatment was administered by Dr. Michael Badruddoja and Dr. Matthew McFarlane, marking a significant milestone in NuvOx’s mission to address unmet needs in patients with a

Tucson, AZ –March 4, 2026, NuvOx Therapeutics, Inc. (“NuvOx”) today announced that the U.S. Food and Drug Administration (FDA) has authorized NuvOx to proceed with a new Phase II clinical trial evaluating NuvOx’s product candidate NanO 2 (the active pharmaceutical ingredient of which is dodecafluoropentane) for the treatment of recurrent high-grade gliomas. The study, titled REBORN (Radiation Enhancement with Bevacizumab, Lomustine, Oxygen Replenishment, and NanO 2 [DDFPe]

Tucson, AZ –December 15, 2025, NuvOx Therapeutics, Inc. (“NuvOx”) announced that the first patient has been enrolled in the Phase IIb NOVEL trial (NanO 2 in Large Vessel Occlusion Stroke (NOVEL): a multicenter single-blind, randomized, placebo-controlled biomarker end point clinical trial of perfluorocarbon in acute ischemic stroke due to large vessel occlusion (LVO). The NOVEL trial is funded by the Efficacy and Mechanism Evaluation (EME) Program, a partnership between t